



Perkumpulan
International Pharmaceutical
Manufacturers Group

IPMG

Strengthening Our Commitment to Health Through Relentless Innovations

ANNUAL REPORT
2023



Table of Contents

Letter from the Chairman of IPMG	4
--	---

CHAPTER 1

ABOUT IPMG

a. IPMG at a Glance	8
b. Vision, Mission, and Goals	10
c. Board Composition	12
d. IPMG Membership	16
e. Members' Profile	17

CHAPTER 2

IPMG in 2023

a. IPMG's Contribution to Indonesia's Healthcare System Transformation in 2023	46
b. Key Activities	48
c. IPMG General Member Meetings	54
d. Members' Contribution to Indonesia	55
e. Members' Awards and Recognitions	74

CHAPTER 3

IPMG'S PRIORITIES

a. Key Priorities and Task Force Activities in 2023	80
b. 2024 Priorities	88

IPMG Secretariat	90
------------------------	----

ANNUAL REPORT
2023 in English

1-91

LAPORAN
TAHUNAN 2023
dalam Bahasa
Indonesia


92-183

Letter
from the
Chairman
of IPMG



we will double down on the same focus areas and strive to strengthen our partnership to drive better health and greater investment in medicines and vaccines, improve prevention and health equity, and deliver a sustainable healthcare system.

We, the IPMG, can reflect on an eventful and successful year. Following our restructuring in 2022, last year was a period of real progress, both in terms of engagement with our members and with the Ministry of Health and government bodies in seeking to expand access to innovative medicines and promote pro-growth policies for the benefit of Indonesian patients and the economy.



We introduced four key objectives, designed to reflect the key issues within the Indonesian healthcare environment. Access to new medicines, transparency in government procurement, localization barriers and recognition of innovation were the focus of all our advocacy and engagement activities.

In pursuing the IPMG mission, we:

1. Worked closely with the Directorate General of Pharmaceutical and Medical Device to establish collaboration and strategic partnership to address access-related challenges: availability of new medicines, price, affordability of innovative drugs, public procurement processes, and competitiveness of Indonesia market for biopharmaceutical Foreign Direct Investors (FDI).
2. Produced a consolidated input for the Omnibus Health Bill.
3. Strengthened task forces' engagement with Badan POM, BPJS Kesehatan, Center for Health Financing and Decentralization Policy (MoH), University of Indonesia Center for Social Security Studies, Indonesia Chamber of Commerce (KADIN), European Chamber of Commerce, American Chamber of Commerce, Corruption Eradication Commission (KPK) and sister associations including Japanese Pharmaceutical Manufacturers Association and The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), to advance IPMG mission.

I was delighted that the association was able to cover a lot of ground in 2023, and I am confident that we have the right team in place, including our board, to take up the new challenges facing the sector head-on.

In the year ahead, we will double down on the same focus areas and strive to strengthen our partnership to drive better health and greater investment in medicines and vaccines, improve prevention and health equity, and deliver a sustainable healthcare system.

The opportunities that lie ahead for the national pharmaceutical and biotechnology industry in a globally dynamic environment are vast. The fast-moving pace of innovations we are seeing in the sector requires a supportive funding environment and regulatory agencies that are agile and ready to keep up in this fast-moving environment.

If Indonesia were to maximize these opportunities and become a high-income country in 2045, the financial and JKN climate must be conducive to innovation. We look forward to working with all our stakeholders to provide that setting and drive better health for all Indonesians.

Dr. Ait-Allah Mejri

Chairman of IPMG





CHAPTER 1

ABOUT IPMG

a. IPMG at a Glance.....	8
b. Vision, Mission, and Goals.....	10
c. Board Composition	12
d. IPMG Membership	16
e. Members' Profile.....	17



IPMG at a Glance

IPMG represents innovative research-based biopharmaceutical companies, small, medium, and large, operating in Indonesia.

IPMG seeks to play an important role as a Partner to the HealthCare Stakeholders in improving Indonesia's healthcare system. IPMG communicates the role and contribution of R&D-based pharmaceutical manufacturers in helping people improve their quality of life as well as pushing for an advancement of an effective and integrated healthcare system in Indonesia.

1. To represent the opinions and interests of IPMG members in discussions with the government, regulatory agencies, trade associations, professional associations, and local national pharmaceutical business.
2. To promote and safeguard members' interests in Indonesia by striving to influence policy developments affecting the health sector.
3. To analyze and interpret the trends and the impacts of changes in legislation relating to the industry.





Our Commitment

Over the years, pharmaceutical companies have developed countless new drugs to manage diseases and mitigate patient suffering. With the specter of new diseases constantly on the horizon, this commitment to research and development is an ever-present imperative. IPMG members assume such responsibility with passion and dedication.

To ensure fair market practices, IPMG aims to create a favorable business climate, adhere to existing government laws and regulations, and uphold our Code of Marketing Practices.

4. To keep abreast of global developments in pharmaceutical policies through IPMG's international representation as a member of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA).





Vision, Mission, and Goals

VISION

IPMG seeks to be a trusted partner to the government of Indonesia and other stakeholders and to play an important role in improving the healthcare system through its members' core strengths, namely medical innovation and the manufacturing of products that meet international standards of pharmaceutical quality and safety.






MISSION

1. IPMG is committed to working as a true partner of the government of Indonesia and across the healthcare spectrum to promote pro-growth and pro-innovation policies for the benefit of Indonesian patients and the economy.
2. IPMG pledges to uphold the highest ethical and safety standards and comply with all applicable domestic and foreign laws and regulations, consistent with the trust placed in our industry by patients and the public.
3. IPMG works with the government of Indonesia and across the healthcare spectrum to achieve the best possible health outcome for citizens while maintaining the sustainability of JKN and supporting the government's priority of developing the pharmaceutical industry.

GOALS

1. Ensuring access to innovative medicines.
2. Co-creating the new life-sciences ecosystem.
3. Building partnerships across the healthcare spectrum.



Board Composition

2023

Board of
Management



Ait-Allah Mejri

PT ROCHE INDONESIA

- ❖ Chairman
- ❖ Sponsor of Partnering for Health Advancement Task Force



Evie Yulin

PT MERCK Tbk

- ❖ Vice Chairwoman
- ❖ Sponsor of Affordability Task Force



Andreas Gutknecht

PT TAKEDA INNOVATIVE
MEDICINES

- ❖ Honorary Treasurer



Selly Kartika

PT ABBOTT INDONESIA

- ❖ Honorary Secretary
- ❖ Sponsor of Regulatory Affairs Task Force



M. Idham Hamzah

PT TRANSFARMA
MEDIKA INDAH (MENARINI)

- ❖ Sponsor of Industrial Policy Task Force



Khalid Ibrahim

PT NOVARTIS INDONESIA

- ❖ Sponsor of Ethics, Medical, Patient Safety Task Force



Nora Siagian

PT PFIZER INDONESIA

- ❖ Sponsor of JKN Drug Enlistment Task Force



George Stylianou

PT MERCK SHARP &
DOHME INDONESIA

- ❖ Sponsor of Communications Task Force

2023

Board of
Supervisors



Hanadi Setiarto

PT ACTAVIS INDONESIA



Ritesh Mishra

PT BOEHRINGER
INGELHEIM INDONESIA

2024-
2026Board of
Management**Ait-Allah Mejri**

PT ROCHE INDONESIA

- ❖ Chairman
- ❖ Sponsor of Partnering for Health Advancement Task Force

**Evie Yulin**

PT MERCK Tbk

- ❖ Vice Chairwoman
- ❖ Sponsor of Market Access Task Force

**Andreas Gutknecht**PT TAKEDA INNOVATIVE
MEDICINES

- ❖ Honorary Treasurer

**Selly Kartika**

PT ABBOTT INDONESIA

- ❖ Honorary Secretary
- ❖ Sponsor of Regulatory Affairs Task Force

**M. Idham Hamzah**PT TRANSFARMA
MEDIKA INDAH

- ❖ Sponsor of Industrial Policy Task Force

**Sreerekha
Sreenivasan**PT NOVO NORDISK
INDONESIA

- ❖ Sponsor of Ethics, Medical, Safety Task Force



Hanadi Setiarto

PT ACTAVIS INDONESIA



George Stylianou

PT MERCK SHARP &
DOHME INDONESIA

❖ Sponsor of Communications
Task Force

2024-
2026

Board of
Supervisors




**Manishkumar
Munot**

PT GLAXO WELLCOME
INDONESIA (GSK)





Dewi Koesoema

PT ASTELLAS PHARMA
INDONESIA



IPMG Membership






Members' Profile

PT Abbott Indonesia

Since its establishment in 1971, PT Abbott Indonesia has served the medical community with a broad range of quality healthcare products, and strives to meet the healthcare needs of Indonesian doctors and consumers. We create breakthrough products – in diagnostics, medical devices, nutrition, and established pharmaceuticals – that help you, your family, and your community lead healthier lives full of unlimited possibilities. Commercial operations for PT Abbott Indonesia are headquartered in Jakarta, while manufacturing and warehousing facilities are located in Cimanggis, Depok.

HEADQUARTER

Chicago, IL, USA



FOCUS OF THERAPEUTIC AREAS

- ✦ Neuroscience ✦ Cardiovascular
- ✦ Women's Health ✦ Pediatrics
- ✦ Vaccines ✦ Vitamins

CONTACT US


Pondok Indah Office Tower 2, Suite 1000,
Jl. Sultan Iskandar Muda Kav. V-TA,
Jakarta 12310, Indonesia
Telephone: +62 21 2758 7888
Website: www.abbott.co.id


500

EMPLOYEES


1

DISTRIBUTORS
& PARTNERS


2

MANUFACTURING
SITES &
WAREHOUSES


20

PRODUCTS/
BRANDS


PT Actavis Indonesia

PT Actavis Indonesia is part of Actavis Generics, a global pharmaceutical company focused on developing, manufacturing, and commercializing branded pharmaceuticals, generic and over-the-counter medicines, and biological products. Our portfolio comprises best-in-class products that provide valuable treatments for the central nervous system, gastroenterology, women's health, cardiovascular system, oncology, and anti-infective therapeutic categories.

We operate the biggest global generics business, providing patients worldwide with increased access to affordable, high-quality medicines in more than 60 countries. Our research and development focuses on the strategic development of innovative and durable value-enhancing products within brand, generic, biological, and OTC portfolios. We are committed to increasing access to quality health solutions and have an unparalleled impact on patients and healthcare systems worldwide.

HEADQUARTER

Swensweg, GA Haarlem,
Netherland



FOCUS OF THERAPEUTIC AREAS

♦ Nervous System ♦ Systemic
 Anti-Infectives ♦ Consumer
 Health ♦ OTC ♦ Cardiovascular
 System ♦ Musculoskeletal
 ♦ G. U. System ♦ Respiratory
 ♦ Oncology ♦ Dermatology

CONTACT US

Jl. Raya Bogor Km. 28, Jakarta 13710,
 Indonesia
 Telephone: +62 21 871 0311
 Fax: +62 21 871 0044
 Website: www.actavis.co.id

254

EMPLOYEES

4

DISTRIBUTORS
& PARTNERS

1

MANUFACTURING
SITES &
WAREHOUSES

97

PRODUCTS/
BRANDS

PT Anugerah Pharmindo Lestari


Member of Zuellig Pharma

PT Anugerah Pharmindo Lestari (APL), a member of Zuellig Pharma, has been successfully serving the Indonesian healthcare market since 1985. APL was founded by DR. Biantoro Wanandi's dream of having a world-class distribution company in Indonesia. Our main purpose is to make healthcare more accessible to the community we serve. We provide world class distribution, commercial, and digital and data analytics services to support the growing healthcare needs across the complex geography and multi-channel environment of Indonesia. Our people serve over 60,000 medical facilities in 434 cities and work with over 60 clients, including the top 10 pharmaceutical companies in the world. We operate a state-of-the-art national distribution center, a regional distribution center, and 25 pharma-grade warehouses.

At APL, we are dedicated to building a healthier future for Indonesia through our sustainability vision, which is rooted in four key pillars. We improve health outcomes by collaborating with our stakeholders, nurturing talent through education and professional growth, respecting the environment by adopting sustainable practices, and setting the highest integrity standards in all our operations. Our integrated approach not only supports but also strengthens the communities we serve in Indonesia, paving the way for a resilient and sustainable future.

HEADQUARTER

Jakarta, Indonesia



FOCUS OF THERAPEUTIC AREAS

❖ Oncology ❖ Diabetes ❖ Hypertension ❖ Cardio-metabolic ❖ Cough and Cold / CHC ❖ Pain Management ❖ Immunology ❖ Women's Health

CONTACT US

World Trade Center (WTC) 1, 15th Floor
Jl. Jenderal Sudirman Kav. 29-30,
Jakarta 12920
Telephone: +62 21 2168 4084
Fax.: +62 21 2168 4085
Email: info@aplcare.com

3,000

EMPLOYEES

1

DISTRIBUTORS
& PARTNERS

27

MANUFACTURING
SITES &
WAREHOUSES

31


PRODUCTS/
BRANDS

PT Astellas Pharma Indonesia

PT Astellas Pharma Indonesia was established in 2000 as PT Yamanouchi Indonesia, a subsidiary of Yamanouchi Pharmaceutical Co., Ltd., a pharmaceutical company based in Japan. On April 1, 2005, Astellas Pharma Inc. was established through a merger of Yamanouchi Pharmaceutical Company Limited and Fujisawa Pharmaceutical Company Limited. Following this merger, PT Yamanouchi Indonesia changed its name to PT Astellas Pharma Indonesia.

HEADQUARTER

Tokyo, Japan



FOCUS OF THERAPEUTIC AREAS

❖ Urology ❖ Oncology ❖
Transplantation

CONTACT US

Plaza Oleos, 5th Floor
Jl. TB Simatupang No. 53A,
Jakarta Selatan 12520, Indonesia
Telephone: +62 21 2278 0171
Website: www.astellas.com



EMPLOYEES



DISTRIBUTORS
& PARTNERS



MANUFACTURING
SITES &
WAREHOUSES




PRODUCTS/
BRANDS

PT AstraZeneca Indonesia

AstraZeneca is a global, science-led, patient-focused pharmaceutical company. AstraZeneca is one of the world's leading biopharmaceutical companies, active in more than 100 countries and engaged in the research, development, manufacture, marketing, and distribution of pharmaceutical products and the supply of healthcare services.

PT AstraZeneca Indonesia ("AZI") was established in 1999. AZI is engaged in the sales, marketing, and distribution of AstraZeneca pharmaceutical products in the Indonesian market. In 2010, AZI Cikarang production was established and inaugurated by the Indonesian Minister of Health, providing toll manufacturing services to affiliate parties.

HEADQUARTER
Cambridge,
United Kingdom



FOCUS OF THERAPEUTIC AREAS

- ❖ Cardiovascular, Renal and Metabolism
- ❖ Respiratory and Immunology
- ❖ Oncology
- ❖ Vaccines & Immunotherapy
- ❖ Rare Disease

CONTACT US


Perkantoran Hijau Arkadia
Jl. TB Simatupang Kav. 88
Tower G, 16th Floor
Kebagusan, Ps. Minggu, Kota Jakarta Selatan, Jakarta 12520, Indonesia
Telephone: +62 21 2997 9000
Website: www.astrazeneca.com


529


EMPLOYEES


2

DISTRIBUTORS
& PARTNERS


2

MANUFACTURING
SITES &
WAREHOUSES


29

PRODUCTS/
BRANDS

PT Bayer Indonesia


Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. In line with its mission, "Health for all, Hunger for none," the company's products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, Bayer aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability, and quality throughout the world. In 2023, Bayer employed around 100,000 people and had sales of 47.6 billion Euros. R&D expenses before special items amounted to 5.8 billion Euros. For more information: www.bayer.com.

Bayer products have been available in Indonesia since 1920. As a legal entity, PT Bayer Indonesia was established in 1957. Our business operations are managed in three business divisions: Pharmaceuticals, Consumer Health, and Crop Science that are supported by Business Partners in the Enabling Functions. Bayer operates three supply centers in Indonesia that are part of the global Bayer supply chain of manufacturing facilities. The majority of products from both supply centers are exported to countries around the world, as well as marketed in Indonesia.

Our business success is largely attributable to the knowledge, skills, and passion of our employees. It is their ability to innovate and their willingness to embrace continuous professional and self-development that drive our position as a world-class innovation company. Bayer Indonesia employs about 900 people around Indonesia in 2023.

HEADQUARTER

Leverkusen,
Germany




FOCUS OF THERAPEUTIC AREAS

- ✦ Cardiovascular ✦ Women's Healthcare
- ✦ Ophthalmology
- ✦ Oncology ✦ Anti-allergy
- ✦ Cancer ✦ Radiology
- ✦ Nutritions

CONTACT US

Menara Astra, 33rd Floor
Jl. Jend. Sudirman Kav. 5-6, Jakarta 10220, Indonesia
Telephone: +62 21 3049 1111
Email: contact.indonesia@bayer.com
Website: www.bayer.com




B. Braun Indonesia

Since entering Indonesia in the 1980s through a local distributor company, B. Braun Indonesia has positioned itself to emerge as one of Indonesia's leading global medical technology and pharmaceutical companies. In facing the road ahead, B. Braun Indonesia has transformed in response to the latest medical technology and established a new pharmaceutical factory in Karawang in July 2017. B. Braun Indonesia owns two legal entities: PT B. Braun Medical Indonesia and PT B. Braun Pharmaceutical Indonesia.

HEADQUARTER

Melsungen, Germany



FOCUS OF THERAPEUTIC AREAS

- ❖ Infection Prevention & Control
- ❖ Minimally Invasive Surgery
- ❖ Oncology ❖ Pain Therapy
- ❖ Surgical Power Systems
- ❖ Dental Care ❖ Infusion Therapy
- ❖ Neurosurgery
- ❖ Spine Surgery ❖ Sutures & Surgical Specialties
- ❖ Extracorporeal Blood Treatment Therapies
- ❖ Interventional Vascular Therapy
- ❖ Nutrition Therapy ❖ Surgical Instruments & Sterile Container Systems
- ❖ Wound Management

CONTACT US

Tempo Scan Tower, 30th Floor
Jl. H.R. Rasuna Said Kav. 3-4, Jakarta Selatan 12950, Indonesia
Telephone: +62 21 5290 7177
Website: www.bbraun.co.id
www.braun.com
Facebook: Braun Indonesia
LinkedIn: B Braun Group

500+

EMPLOYEES



8

DISTRIBUTORS
& PARTNERS



2

MANUFACTURING
SITES &
WAREHOUSES



13

PRODUCTS/
BRANDS


PT Boehringer Ingelheim Indonesia

Boehringer Ingelheim is working on breakthrough therapies that transform lives, today and for generations to come. As a leading research-driven biopharmaceutical company, it creates value through innovation in areas of high unmet medical need. Founded in 1885 and family-owned ever since, Boehringer Ingelheim takes a long-term, sustainable perspective. Over 53,000 employees serve over 130 markets in the two business units, Human Pharma and Animal Health. Learn more at www.boehringer-ingelheim.com.

Boehringer Ingelheim entered the Indonesian market in 1969, and in 2001, PT Boehringer Ingelheim Indonesia was established. Starting July 1, 2021, Boehringer Ingelheim Indonesia changed its Human Pharma commercial model with PT Anugerah Pharmindo Lestari (APL) - a member of Zuellig Pharma, for commercial and medical activities in Indonesia. Boehringer Ingelheim Indonesia continues to be committed to maintaining its footprint in Indonesia and supporting effective treatment to patients.

HEADQUARTER

Ingelheim am Rhein,
Germany



CONTACT US

Sequis Tower, Level 22 Unit 5
Jl. Jend. Sudirman Kav. 71, South Jakarta
12190, Indonesia



148

EMPLOYEES



1

DISTRIBUTORS
& PARTNERS



1

MANUFACTURING
SITES &
WAREHOUSES

PT Eisai Indonesia

In 1968, the company established marketing operations in Indonesia, and by 1970, it was established as PT Eisai Indonesia. We developed our plantation research facility in Tjianjur in 1976, then moved to Citeureup in 1987 until the present day. 1989 saw the first export to Japan.

By 1990, we had expanded exports to Thailand. Eisai has a very strong philosophy: when conducting business in human health care (HHC), it reflects our commitment to activities that increase benefits for patients, their families, and consumers.

HEADQUARTER

Tokyo, Japan




FOCUS OF THERAPEUTIC AREAS

- ❖ Oncology ❖ Neurology
- ❖ Gastrointestinal

CONTACT US

Trinity Tower 10th floor
Suites 09-15
Jl. HR Rasuna Said No.6.
Karet Kuningan, Setiabudi
Jakarta 12940.




PT Glaxo Wellcome Indonesia (GSK)



400+

EMPLOYEES




1
DISTRIBUTORS
& PARTNERS


2
MANUFACTURING
SITES &
WAREHOUSES


39
PRODUCTS/
BRANDS

HEADQUARTER

Brentford,
United KingdomFOCUS OF
THERAPEUTIC AREAS

Pharmaceutical Medicines:

- ✦ Respiratory Disease ✦ Urology
- ✦ Allergy ✦ Neurology

Vaccines to Protect from Virus:

- ✦ Pneumonia ✦ Rotavirus
- ✦ Diphtheria ✦ Tetanus ✦ Pertussis
- ✦ Varicella ✦ Hepatitis ✦ HPV
- ✦ Influenza ✦ Herpes Zoster

CONTACT US

RDTX Square 19th Floor
Jl. Prof. Dr. Satrio, No. 164, Setiabudi,
Jakarta 12930, Indonesia
Telephone: +62 21 2553 2350
Faximile: +62 21 2553 2360
Email: cga.indonesia@gsk.com
Website: www.gsk.com

We are a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. We aim to positively impact the health of 2.5 billion people over the next 10 years. We make innovative vaccines and specialty medicines to prevent and treat disease. Our R&D focuses on the science of the immune system, human genetics, and advanced technologies. We have developed monoclonal antibodies to help treat different diseases.

Our vaccine portfolio is the broadest in the industry, helping protect people from meningitis, shingles, flu, polio, measles, and many more. Two million of our vaccines are administered every day, and 40 percent of the world's children receive a GSK vaccine each year. Since 2017, we've delivered 13 major approvals and more than doubled the number of potential new vaccines and medicines we have in Phase 3 and registration to 23.

Our bold ambitions for patients are reflected in new commitments to growth and a step-change in performance. We employ over 70,000 people and have a presence in more than 80 countries worldwide. We are ranked 1st in the Access to Medicine Index for people in low- to middle-income countries. This reflects the company's clear access-to-medicine strategy embedded within the overall company strategy and the application of its scientific innovation to address global health priorities. We have the largest R&D pipeline, targeting priority diseases that impact people in low- and middle-income countries.

We have been in Indonesia for more than 50 years and have invested in a manufacturing facility in Pulogadung. We have a long history of supporting our communities in times of need and have taken deliberate steps through concrete actions to partner with healthcare associations and governments. We are a company where outstanding people can thrive. Today, GSK Indonesia employs more than 400 highly skilled Indonesian talents and is committed to continuously optimizing employment opportunities in Indonesia. In 2022, we received a special award from Governor of DKI Jakarta Province as an E-Waste Cared Company; in 2023, we received a Gold Award from BPOM Environmentally Sustainable Corporate Governance, and we also won Top Employer Indonesia 2024. We will continue to leverage access to innovative medicines and vaccines to positively impact millions of Indonesians and build a better healthcare ecosystem in Indonesia together.

PT Johnson and Johnson Indonesia Two

PT Johnson and Johnson Indonesia Two (also known as PT Johnson & Johnson Indonesia) is the local operating company of Johnson & Johnson, the world's largest and most broadly-based healthcare company. Established in Indonesia in 1973, the company engages in three business sectors: consumer health, pharmaceuticals, and medical technology (including Vision).

HEADQUARTER

New Jersey, USA



FOCUS OF THERAPEUTIC AREAS

- ❖ Oncology ❖ Immunology
- ❖ Neuroscience (Psychiatry & Neurology) ❖ Infectious Diseases & Vaccines
- ❖ Pulmonary Hypertension
- ❖ Pain Management

CONTACT US


K-Link Tower 15th Floor
Gatot Subroto Kav. 59A, Jakarta 12950




EMPLOYEES



DISTRIBUTORS
& PARTNERS



MANUFACTURING
SITES &
WAREHOUSES



PRODUCTS/
BRANDS

PT Meiji Indonesia

PT Meiji Indonesia has pioneered high-quality antibiotics since its foundation in 1974. Initially a subsidiary of Japan-based Meiji Seika Kaisha Ltd. (now operating as Meiji Seika Pharma Co., Ltd.), PT Meiji Indonesia is one of the few players in the pharmaceutical sector, delivering the highest quality production standards in Indonesia. After more than four decades of helping to improve the nation's health, PT Meiji Indonesia looks forward to the decades ahead.

HEADQUARTER

Tokyo, Japan



FOCUS OF THERAPEUTIC AREAS

❖ Antibacterial ❖
Ophthalmology ❖ Lipid
Regulator ❖ Osmotic Laxative
❖ Gastrointestinal Disorder

CONTACT US


Jl. Prof. Dr. Soepomo No. 40, Tebet
Jakarta Selatan 12870, Indonesia
Telephone: +62 21 2138 3388
Website: www.meiji.co.id




EMPLOYEES



DISTRIBUTORS
& PARTNERS



MANUFACTURING
SITES &
WAREHOUSES



PRODUCTS/
BRANDS

PT Merck Tbk


PT Merck Tbk is an affiliate of Merck KGaA, Germany ("Merck"). Merck is a vibrant science and technology company with 353 years of global footprint. Science is at the heart of everything we do. It drives the discoveries we make and the technologies we create. We make a positive difference to millions of people's lives every day. Our constant curiosity and specialist approach drive our partnerships and bring new ideas to life, from advancing gene editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices. Our work is fueled by our belief in science as a force for good. We work to enhance the human experience and create more joyful and sustainable ways to live.

We believe scientific exploration and responsible entrepreneurship are key to technological advances that benefit us all. This is how Merck has thrived since 1668. We will continue to push the boundaries of possibility to create opportunities for everyone. This is what drives us. This is what we work for. This is our future.

In Indonesia, Merck was established on October 14, 1970, and transformed into a public company in 1981. PT Merck Tbk runs Merck's healthcare business and focuses on discovering, developing, manufacturing, and marketing innovative prescription medicines. For more than 50 years, we have existed in Indonesia and maintained our focus on patient lives. The transformation has strengthened our focus in the changing world, re-emphasizing our respect toward life and our responsibility to improve the quality of life.

HEADQUARTER

Darmstadt, Germany



FOCUS OF THERAPEUTIC AREAS

♦ Oncology ♦ Multiple Sclerosis ♦ Growth Hormone Disorder
 ♦ Cardiovascular Disease ♦ Diabetes ♦ Thyroid Disorders ♦ Infertility Treatment Portfolio
 ♦ Advanced Fertility Technologies and Devices

CONTACT US

Jl. TB Simatupang No.8, Pasar Rebo
 Jakarta Timur 13760, Indonesia
 Telephone: +62 21 2856 5600
 Faximile: +62 21 2856 5601
 Email: contact.id@merckgroup.com

Marketing Office Arkadia Green Park, G
 Tower, 10th Floor
 Jl. TB Simatupang Kav.88, Pasar Minggu,
 Jakarta Selatan 12520, Indonesia Telephone
 +62 21 2856 5600 Fax +62 21 2856 5601



www.merck.co.id



Merk indonesia



@merckindonesia



MerckIndonesia



Merck Indonesia



381

EMPLOYEES



1

DISTRIBUTORS
& PARTNERS



1

MANUFACTURING
SITES &
WAREHOUSES



20


PRODUCTS/
BRANDS

PT Mitsubishi Tanabe Pharma Indonesia

We opened our doors in Indonesia on July 25, 1970, under PT Tanabe Abadi, a joint venture between Tanabe Seiyaku Co., Ltd., Osaka, Japan, and N.V. Pharmacie Nasional, Bandung, Indonesia. PT Tanabe Abadi began its commercial production at the manufacturing site located on Jl. Dr. Setiabudi, Bandung. To increase production capacity and maintain product quality, we decided to relocate the manufacturing site to the current Jl. Rumah Sakit, Ujungberung, Bandung on March 29, 1986. With the change in capital structure and the aim of expanding the business network, on June 1, 2003, the company name was changed to PT Tanabe Indonesia.

On October 1, 2007, the holding company Tanabe Seiyaku Co., Ltd. merged with Mitsubishi Pharma Corporation and formed the newly named Mitsubishi Tanabe Pharma Corporation. On October 1, 2018, the company name was changed to PT Mitsubishi Tanabe Pharma Indonesia. As a subsidiary of Mitsubishi Tanabe Pharma Corporation, Osaka, Japan, we are engaged in the pharmaceutical industry, focusing on producing and selling ethical products for domestic and overseas markets. We do our utmost to contribute to Indonesian society and improve the Indonesian people's quality of life by supplying them with our high-quality products.

HEADQUARTER
Osaka, Japan



FOCUS OF THERAPEUTIC AREAS

❖ Cardiovascular ❖
Metabolism ❖ Immuno-
inflammatory ❖ Anesthetics
❖ Antipsychotics ❖ Central
Nervous System

CONTACT US

Jl. Tanah Abang III No. 8, Kelurahan Petojo
Selatan, Kecamatan Gambir
Jakarta Pusat 10160, Indonesia
Telephone: +62 21 3841 842
Website: www.mt-pharma-id.com

300+

EMPLOYEES

1

DISTRIBUTORS
& PARTNERS

2

MANUFACTURING
SITES &
WAREHOUSES

46


PRODUCTS/
BRANDS

PT Mundipharma Healthcare Indonesia

Mundipharma has over 60 years of experience in pain management and antisepsis, with a worldwide marketing reach. Mundipharma is dedicated to addressing the urgent needs of healthcare professionals and patients. Mundipharma delivers high-quality products, with a mission to alleviate the suffering of patients and substantially improve their quality of life.

Mundipharma is committed to presenting patients with severe illness and pain with new treatment options in the fields of pain management, oncology, oncology supportive care, respiratory, consumer health, and ophthalmology. Mundipharma is present in Indonesia through its representative office, Mundipharma Laboratories GmbH, and for consumer health business under Mundipharma Healthcare Indonesia in 2015. We are currently focusing on consumer health through the Betadine brand, which has been trusted by hospitals and households to prevent and treat infection.

HEADQUARTER
Cambridge,
United Kingdom



FOCUS OF THERAPEUTIC AREAS

✦ Upper Respiratory Tract
Infection ✦ Feminine
Care ✦ Wound Care ✦
Supportive Care

CONTACT US


Generali Tower Gran Rubina, Business Park,
20th Floor
Kawasan Rasuna Epicentrum, Jl. H. R.
Rasuna Said Kav. C-22
Jakarta 12940, Indonesia
Telephone: +62 21 8065 7300
Website: www.mundipharma.com



EMPLOYEES



DISTRIBUTORS
& PARTNERS



MANUFACTURING
SITES &
WAREHOUSES



PRODUCTS/
BRANDS

PT Merck Sharp & Dohme Indonesia (MSD)

Merck & Co., Inc. New Jersey (NJ), United States (US) was founded on January 1, 1891. George Merck, age 23, established the company in the US to distribute fine chemicals throughout New York City and its neighboring areas. Outside of the US and Canada, Merck & Co., Inc., New Jersey, US, is known as Merck Sharp & Dohme (MSD). MSD aspires to be the premier research-intensive biopharmaceutical company. We're at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals.

For more than 130 years, we brought hope to humanity through the development of important medicines and vaccines. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable, and healthy future for all people and communities. Our purpose: We use the power of leading-edge science to save and improve lives around the world.

We're a global healthcare company working to deliver innovative health solutions through our medicines, vaccines, biologic therapies, and animal health products. We're focused on discovering new solutions for today and the future. From finding solutions for some of the world's most debilitating diseases to getting our medicines and vaccines to those in need and building more effective health systems, we're always on a mission to create a better world. MSD is a trade name of Merck & Co., Inc., with headquarters in Kenilworth, New Jersey, the US. PT Merck Sharp & Dohme Indonesia was established in 2005 and currently focuses on our main therapeutic areas, namely, oncology and vaccines.

HEADQUARTER

Rahway, New Jersey,
USA



FOCUS OF THERAPEUTIC AREAS

❖ Oncology ❖ Vaccines

CONTACT US

Wisma BNI 46, 27th Floor
Jl. Jend. Sudirman Kav. 1, Jakarta 10220,
Indonesia
Telephone: +62 21 5789 7000
Faximile: +62 21 5789 7099
Website: www.msd-indonesia.com



±170

EMPLOYEES



2

DISTRIBUTORS
& PARTNERS



1

MANUFACTURING
SITES &
WAREHOUSES



16

PRODUCTS/
BRANDS


PT Novartis Indonesia

Harnessing innovation on a global scale, Novartis is reimagining medicine to improve and extend patients' lives. Novartis' mission is to discover breakthrough treatments and find new ways to deliver them to patients. Headquartered in Basel, Switzerland, Novartis has a rich history spanning over 200 years. In Indonesia, Novartis contributes to improving the quality of Indonesian patients' lives through its expertise in cardiovascular, dermatology, autoimmune diseases, retina, and oncology.

Through its operations in manufacturing and commercializing medicines in Indonesia, Novartis looks to its social, environmental, and economic impact. Novartis investments and activities include its manufacturing facility in Pasar Rebo, Jakarta, its contributions to the world's largest universal health coverage (JKN), its Continuing Medical Education for healthcare professionals across the country, and the Disease Awareness initiatives it conducts for laymen. Novartis Indonesia is proud to renew its longstanding commitment.

HEADQUARTER

Basel, Switzerland




FOCUS OF THERAPEUTIC AREAS

- ❖ Cardiovascular ❖ Oncology
- ❖ Immunology

CONTACT US

AXA Tower, 26th Floor, Kuningan City
Jl. Prof. Dr. Satrio Kav. 18, Kuningan
Setiabudi, Jakarta 12940, Indonesia
Telephone: +62 21 3048 0600
Email: communication.indonesia@novartis.com
Website: www.id.novartis.com



PT Novo Nordisk Indonesia


Novo Nordisk is a global healthcare company from Denmark with more than 100 years of innovation and leadership in healthcare. Our purpose is to drive change to defeat chronic severe diseases. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure the diseases we treat. In Indonesia, we have been translating the unmet medical needs of people living with a serious chronic disease into innovative medicines. Our treatments benefit patients living with diabetes and rare diseases.

We have been working closely with the Indonesian MoH since the beginning of our establishment in Indonesia. Novo Nordisk has also been appointed as the implementing partner for the Indonesian MoH and the Danish MoH's joint action plan to address diabetes and chronic disease prevention and management in Indonesia since 2021. As the implementing partner, Novo Nordisk has started several programs to address the issue, e.g. Affordability Project, Changing Diabetes in Children, and Tanya Gendis – a diabetes chatbot. Additionally, we have conducted real-world evidence studies, such as the DIAPRIM (diabetes in primary care) study, which revealed a crucial insight: shifting insulin initiation from advanced facilities to primary care in Indonesia could reduce the Jaminan Kesehatan Nasional (JKN) diabetes budget by 14%, potentially saving an estimated Rp1.7 trillion per year. Furthermore, we have organized numerous awareness activities, particularly during the 2023 World Diabetes Day and World Obesity Day.

Novo Nordisk also supports the government's efforts to enhance public health and address affordability. All of Novo Nordisk's insulin and hemophilia products are listed in JKN, Indonesia's universal health coverage, allowing the company to serve people at all economic levels.

HEADQUARTER

Bagsværd, Denmark




FOCUS OF THERAPEUTIC AREAS

- ✦ Diabetes ✦ Hemophilia
- ✦ Growth Disorder

CONTACT US

Pondok Indah Office Tower 5, 20th Floor
Suite 2004-0
Jl. Sultan Iskandar Muda Kav V-TA, Pd.
Pinang, Kec. Kby. Lama
Jakarta Selatan 1231, Indonesia
Telephone: +62 21 2958 1000
Email: NNIDContactUs@novonordisk.com
Website: www.novonordisk.id



PT Organon Pharma Indonesia Tbk

Organon was launched globally on June 1, 2021. Our head office is located in Jakarta and our manufacturing site is in Pandaan, East Java. At Organon, we believe in a better and healthier every day for every woman. We understand that women are foundational to a healthier world.

As a new company, we will begin by listening to women's healthcare needs, big and small, enabling us to develop treatments tailored to them – because we know there is so much more we can do for women and their health. Our mission is to deliver impactful medicines and solutions for a healthier every day. We build upon our firm foundation of more than 60 medicines and solutions across various areas, including reproductive health, heart disease, breast cancer, allergies, and asthma. We bring these important therapies worldwide, with an international footprint serving people in more than 140 markets. The diversity of our business provides a sustainable engine of growth so we can continue to invest and advance new medicines and solutions for women that are so urgently needed.

We believe the journey to improve women's health is critical to achieving a healthier world. Our people—a strong global community of thousands—are united in our drive to support better women's health within our company and around the globe. Together, we work to deliver Organon, who is here for her health.

HEADQUARTER

New Jersey, USA



FOCUS OF THERAPEUTIC AREAS

- ❖ Women's Health
- ❖ Biosimilars ❖ Cardiovascular
- ❖ Dermatology ❖ Non-Opioid Pain

CONTACT US

Sinarmas MSIG Tower, 37th Floor,
Unit 102 & 106
Jl. Jend. Sudirman Kav. 21,
Jakarta 12920, Indonesia

295

EMPLOYEES

3

DISTRIBUTORS
& PARTNERS

2

MANUFACTURING
SITES &
WAREHOUSES

14

PRODUCTS/
BRANDS

PT Otsuka Indonesia

PT Otsuka Indonesia was established in 1974 as a joint venture pharmaceutical company with Otsuka Pharmaceutical Co., Ltd., Japan. Built on an area of 48,397m² in Lawang, a small town in East Java, PT Otsuka Indonesia manufactures and markets medicinal products, such as infusion/injection fluids and ethical drugs, nutritional products for special medical purposes, as well as medical devices.

This step of business diversification undertaken by PT Otsuka Indonesia is constantly growing, not only in Indonesia. We have also expanded our production by exporting products to many countries, such as Hong Kong, Singapore, Malaysia, Myanmar, Vietnam, the Philippines, Mongolia, Sri Lanka, Thailand, India, and Egypt.

For decades, PT Otsuka Indonesia has proven itself to be the leader in the infusion solutions business. To strengthen our position, we continue to challenge ourselves to develop new products that will fulfill customer needs in the future, based on our motto, "Otsuka-people creating new products for better health worldwide."

HEADQUARTER

Tokyo, Japan



FOCUS OF THERAPEUTIC AREAS

❖ CNS ❖ Cardiovascular
❖ Oncology ❖ Clinical
Nutrition ❖ I. V. Solution

CONTACT US

Pondok Indah Office Tower I, 6th Floor
Jl. Sultan Iskandar Muda Kav. V-TA, RT.1/
RW.16, Pd. Pinang, Kec. Kby. Lama
Jakarta Selatan 12310, Indonesia

1,200+

EMPLOYEES

4

DISTRIBUTORS
& PARTNERS

3

MANUFACTURING
SITES &
WAREHOUSES

94

PRODUCTS/
BRANDS

PT Pfizer Indonesia


Pfizer began operations in Indonesia in 1969 when the company employed only 11 employees under the auspices of Pfizer International (Pfizer Inc.). As the business grew, Pfizer Indonesia inaugurated its first manufacturing facility in 1971, highlighting its commitment to advancing Indonesia's pharmaceutical industry. For more than 50 years, Pfizer Indonesia has strived to promote the advancement of Indonesia's health sector by preventing, treating, and curing various diseases.

Pfizer Indonesia operates as a manufacturing facility that produces various medical drugs to meet the needs of domestic and neighboring countries. Supported by more than 300 employees, Pfizer Indonesia provides medicines and health solutions at every stage of life. The company's supply chain has been recognized for implementing good manufacturing practices, showcasing suitable production methods, and environmental management advantages. Through the Pfizer Global Supply Business Unit, Pfizer Indonesia manufactures and exports products in tablets, capsules, and ointments with various brands to South Korea, Malaysia, Singapore, Thailand, the Philippines, Vietnam, Brunei, and Hong Kong.

Pfizer Indonesia has set the standards for high-quality and safe medicines and vaccines. The company has been working with healthcare providers, government agencies, and local communities to expand access to innovative therapeutics. Pfizer Indonesia has partnered with patient groups and an innovative startup to launch Indonesia's first digital patient assistance program. It also collaborates continuously with health practitioners to support local and global initiatives for broader and better access to quality drugs and treatments for patients.

HEADQUARTER

New York, NY, USA



FOCUS OF THERAPEUTIC AREAS

- ❖ COVID-19 Therapies
- ❖ Pneumonia Vaccine
- ❖ Oncology ❖ Hospital Products (including anti-infectives and pain management) ❖ Rare Disease Treatment ❖ Immunology & Inflammation

CONTACT US


World Trade Center 3, 28th Floor
Jl. Jenderal Sudirman Kav. 29-31
Jakarta 12920, Indonesia
Telephone: +62 21 8086 1400
Website: www.pfizer.co.id




EMPLOYEES



DISTRIBUTORS
& PARTNERS



MANUFACTURING
SITES &
WAREHOUSES




PRODUCTS/
BRANDS

PT Roche Indonesia

Throughout our 125-year history, Roche has grown into one of the world's largest biotech companies, as well as a leading provider of in-vitro diagnostics and a global supplier of transformative, innovative solutions across major disease areas, including oncology, neurology, infectious diseases, and ophthalmology. With our combined strengths in pharmaceuticals and diagnostics, we are better equipped to drive personalized healthcare forward – to bring the right treatments to the right patients at the right time.

For more than 50 years in Indonesia, we continue to focus on helping patients in Indonesia live longer, better lives through prevention, diagnostics and treatment and making a sustainable contribution to the nation.




PT Servier Indonesia

Servier is an independent group committed to therapeutic progress, serving patient needs and governed by a non-profit foundation. Currently, there are 150 countries, including Indonesia, in which the group's medicines are distributed. In 1987, PT Parvico Bersaudara was established to promote Servier products. PT Servier Indonesia was legally founded in 2005. The group strongly believes that working with patients at all stages of the medicine's life cycle leads to better care and solutions to support them throughout their journey.

HEADQUARTER

Suresnes, France



FOCUS OF THERAPEUTIC AREAS

❖ Cardiometabolism
❖ Neuroscience ❖ Immuno-
inflammation ❖ Oncology

CONTACT US

Menara Kadin Indonesia, 18th Floor
Jl. R. H. Rasuna Said Blok X-5 Kav 2-3,
RT.1/ RW.2, Kuningan, Jakarta Selatan
12950, Indonesia



150

EMPLOYEES



4

DISTRIBUTORS
& PARTNERS



15

PRODUCTS/
BRANDS


Takeda Indonesia (PT Takeda Indonesia and PT Takeda Innovative Medicines)

At Takeda, creating Better Health for People and a Brighter Future for the World is our purpose. Our values have guided us throughout our over 240-year long history and our ambition remains steadfast. We strive to deliver truly transformative treatments, contributing significant value to society while building an exceptional experience for our people.

Our vision is to discover and deliver life-transforming treatments guided by our commitment to patients, our people, and the planet. This purpose-led and values-based approach is a core foundation of our global growth strategy and long-term value creation for our stakeholders. In our pursuit of global R&D and the country's strategy, we are unwaveringly committed to tackling the most pressing unmet medical needs and overcoming the most formidable challenges in public health.

In Indonesia, Takeda has contributed to the country's healthcare improvement for more than 50 years, since 1971, covering a broad set of expertise, including oncology, gastroenterology, rare diseases, vaccines, and consumer healthcare. We are dedicated to expanding access to our innovative treatments for more patients in Indonesia, fostering enduring partnerships with diverse stakeholders to enhance patient outcomes and sustain the healthcare system in the long term. Our headquarters office is located in Jakarta, with a manufacturing plant in Bekasi, West Java.

HEADQUARTER
Tokyo, Japan




FOCUS OF THERAPEUTIC AREAS

- ❖ Oncology ❖
- Gastroenterology ❖ Rare Diseases ❖ Vaccines
- ❖ Consumer Healthcare

CONTACT US

RDTX Place – 18th Floor
Jl. Prof. DR. Satrio Kav. 3, RT 17 / RW 04,
Kuningan
Jakarta Selatan, Indonesia
Telephone/Telepon: +62 21 8665 9400
Website/Situs Web: www.takeda.com



PT Transfarma Medika Indah (Menarini)


PT Transfarma Medika Indah is an affiliate of Menarini Group. An Italian-based global company with a footprint in Indonesia of more than 30 years. We work towards invigorating the lives of patients and consumers across Indonesia.

The Menarini Group is present in 140 countries around the world. With over 17,000 valuable employees, we work to provide broad therapeutic treatments for cardiovascular, respiratory, pain management, pediatrics, dermatology & aesthetics, oncology, and rare diseases, as well as medical devices and consumer health.

In Indonesia, Menarini employs 415 people across various functions, including operating a GMP and halal-certified facility that supplies domestic and international markets.

HEADQUARTER

Jakarta, Indonesia



FOCUS OF THERAPEUTIC AREAS

❖ Cardiovascular ❖ Respiratory
❖ Pain Management
❖ Pediatrics ❖ Dermatology & Aesthetics
❖ Oncology ❖ Rare Diseases
❖ Medical Devices
❖ Consumer Health

CONTACT US

Unit 802, 8th Floor, Pondok Indah Office
Tower 2 (d/h Wisma Pondok Indah 2)
Jl. Sultan Iskandar Muda Kav. V-TA,
Pondok Indah, Kebayoran Lama
Jakarta Selatan 12310, Indonesia
Telephone: +62 21 7697 323 (hunting)
Faximile: +62 21 7697 528
Website: www.menariniapac.com

415

EMPLOYEES

4

DISTRIBUTORS
& PARTNERS

2

MANUFACTURING
SITES &
WAREHOUSES

51


PRODUCTS/
BRANDS

PT Wellesta CPI Healthcare

Wellesta Indonesia is a healthcare company headquartered in Singapore. It has operated in Indonesia since 2019. We aim to serve clients and consumers through commercial and marketing support using an innovative approach across the Wellesta value chain. Working at full compliance and transparency is our approach to doing business.

HEADQUARTER

Singapore



FOCUS OF THERAPEUTIC AREAS

- ❖ Neuroscience ❖ Pediatrics
- ❖ Oncology ❖ Nephrology
- ❖ Primary Care

CONTACT US

Kirana Three Office Tower, 8th Floor
Jl. Boulevard Raya Kav. 1,
Kelapa Gading Timur
Jakarta Utara 14240, Indonesia
Website/Situs Web: www.wellesta.com



EMPLOYEES



DISTRIBUTORS
& PARTNERS



MANUFACTURING
SITES &
WAREHOUSES



PRODUCTS/
BRANDS







CHAPTER 2

IPMG in 2023

a. IPMG's Contribution to Indonesia's Healthcare System Transformation in 2023.....	46
b. Key Activities	48
c. IPMG General Member Meetings.....	54
d. Members' Contribution to Indonesia	55
e. Members' Awards and Recognitions	74



IPMG's Contribution to Indonesia's Healthcare System Transformation in 2023



Established in
2002



26
multinational
research-based
pharmaceutical
companies



17
local
manufacturing
facilities



57
local warehouse
facilities



**792 &
1,361**
total products
and SKUs



334
(45%)
total products
produced in Indonesia




**252 (32%)
& 365 (27%)**
total products and
SKUs (on JKN)



138
(55%)
total products
produced in Indonesia
(on JKN)

3

number
of clinical
trials in
Indonesia



PEOPLE

**12,167**number of
employees**12,090**number of Indonesian
employees**20**number of employees
with disabilities

PARTICIPATION IN IMPROVED HEALTHCARE

**179,397**number of HCPs participated in
the capacity-building program



Key Activities

Advocating at Omnibus Health Law



Facilitated by KADIN, IPMG Advocated at Health Commission

IPMG was invited to discuss the draft of the omnibus health law with the Health Commission in the People's Representative Council of Indonesia. In the meeting, IPMG conveyed some inputs and shared thoughts and opinions on formulating the omnibus health law.



IPMG at KADIN Focus Group Discussion with the Ministry of Health

IPMG presented three key inputs to the Director General of Pharmaceutical and Medical Devices, Dr. Dra. Lucia Rizka Andalucia, Apt, M.Pharm, MARS, regarding the Omnibus Health Law government regulations development draft at a Focus Discussion Group hosted by KADIN. The topics were Pharmacopeia Indonesia enforcement, price control, and local content requirements.



B.I.M.A Project with Directorate General of Pharmaceutical and Medical Devices Resilience

As a trusted partner, IPMG worked with the Directorate of Pharmaceutical and Medical Devices Resilience to increase the availability and access of innovative medicines through B.I.M.A project.



PhRMA's visit to IPMG

IPMG welcomed the visit of Julian Fabens and Anjam Azis from the Pharmaceutical Research and Manufacturers of America (PhRMA) during their visit to Indonesia. On the occasion, IPMG and PhRMA discussed and exchanged perspectives on Indonesia's healthcare system and how the two can strengthen it by making more contributions and improving patient's access to innovative medicines that are highly efficacious and safe.



With PhRMA, IPMG Visited Head of DPR RI Expertise Body

During PhRMA's visit in Indonesia, both IPMG and PhRMA visited Head of DPR RI Expertise Body (Dr. Inosentius Samsul, S.H., M.Hum.) to discuss on issues around healthcare sector in Indonesia.



IPMG Discussion with PKJS-UI

IPMG was invited to participate in a Focus Group Discussion "Documenting Equity of JKN" with The Center for Social Security Studies of University of Indonesia. In the discussion, IPMG represented the multinational and research-based pharmaceutical industry, sharing insights and opinions around the dynamics of the national health system (JKN) and the pharmaceutical industry's involvement.



Focus Group Discussion at Center for Health Financing and Decentralization Policy

IPMG Market Access Task Force met with dr. Maria Hotnida, MARS, the Head of the Center for Health Financing and Decentralization Policy, to discuss and contribute further to implementing Coordination of Benefit (CoB).



Healthy Market Workshop

IPMG participated in the “Healthy Market Workshop” held by the Ministry of Health and Tony Blair Institute (TBI). The workshop supported the Ministry of Health to develop a deeper understanding of the nature of life sciences investment and what is needed to support engagement and partnerships in Indonesia. In the event, IPMG emphasized the importance of increasing access to innovation and foreign direct investment for Indonesia. The insights from the workshop were said to shape the government’s policy decisions in creating incentives for investment in the Indonesian life sciences market.



Focus Group Discussion with Corruption Eradication Commission (KPK)

IPMG participated in the dialogue between the industry association and the Directorate of Anti-Corruption for Business Entities (Corruption Eradication Commission/ KPK). The agenda of the meeting was to prevent corruption in the business ecosystem, particularly in the healthcare sector. IPMG fully supports all the efforts and initiatives by KPK to prevent the practice of corruption in the healthcare sector. Several inputs were raised through the dialogue regarding business practices in the pharmaceutical industry. All in all, IPMG and KPK are together, hand in hand, aligned to ensure clean and healthy business ethics in the healthcare sector.



IPMG Media Luncheon

IPMG Communications Task Force discussed the low availability and access to innovative medicines with selected media editors to raise public awareness regarding ongoing issues in the healthcare sector in Indonesia.



Pharmaceutical Healthcare Summit 2023

IPMG Vice Chairwoman, Evie Yulin, continued to advocate IPMG messages about raising the urgency to improve the availability and patients' access to innovative medicines and vaccines. On this occasion, Ms. Yulin addressed barriers that hinder innovative medication from coming to Indonesia and recommended utilizing opportunities that may strengthen policy to promote growth and innovation in the pharmaceutical ecosystem.

Ms. Yulin delivered these messages when speaking as one of the distinguished speakers on the first day of The Pharmaceutical and Healthcare Summit 2023 during the "Health Resilience and Accelerating Access to Innovative Medicines" session. Speaking alongside Ms. Yulin, the Director of Pharmaceutical Resilience and Medical Devices, Apt. Roy Himawan, S.Farm., M.Kes., Dr. apt. Ria Christine, M. Kes. (BPOM), and Apt. Drs. Pre Agusta, MBA as moderator.



IPMG Collaboration with Ministry of Health in Commemorating the 59th National Health Day

IPMG held a multi-stakeholders dialogue, "Health for All: National Health Coverage as a Foundation for Building a Strong and Resilient Health System". Speaking at the dialog were Special Staff to the Minister of Health in Public Health Services (MoH) Prastuti Soewondo, President Director of BPJS Kesehatan Ghufron A. Mukti, and Director of Pharmaceutical and Medical Device Resilience (MoH) Roy Himawan.

The objectives of the dialog were to stimulate discussion and connect stakeholders to raise the urgency of improving the quality of national health insurance services for public health, which will contribute to the country's productivity level, and to assess the availability of patient access to comprehensive and quality health services, including obtaining effective and affordable treatment.



IPMG Workshop on Medicine Quality Standards in Indonesia and Indonesian Pharmacopeia Supplements

IPMG conducted a workshop regarding Medicine Quality Standards in Indonesia and Indonesian Pharmacopeia Supplements. The workshop invited pharmaceutical industries with the Indonesian Food and Drug Supervisory Agency (BPOM) to discuss the issues related to the topic.



BPOM Customer Gathering

IPMG was invited to a customer gathering event held by the BPOM. The event commemorated BPOM's milestone in ensuring the quality of food and drugs. As a true partner, IPMG is fully committed to supporting BPOM in upholding the quality and safety of medicines for Indonesian patients.



BPOM Net Zero Program

IPMG collaborated with the BPOM to plant mangroves to support carbon emission reduction programs.





World Anti-Corruption Commemoration Day with KPK


KPK and changemakers nationwide commemorate Global Anti-Corruption Day and affirm the national commitment to fighting corruption and kleptocracy. IPMG, which represents the research-based biopharmaceutical industry, took part in the celebration to declare its stance and commitment to upholding business ethics and integrity.



E-Labeling Workshop

IPMG Regulatory Affairs Task Force collaborated with BPOM to promote and share knowledge related to the ongoing e-labeling pilot project with other relevant stakeholders.





IPMG General Member Meetings



24
FEB
2023

IPMG held the Annual General Members Meeting as a kick-off meeting for 2023. In the meeting, IPMG and its members aligned regarding relevant issues and discussed the advocacy priorities for 2023.



23
OCT
2023

IPMG held a general meeting to connect with all members, realign, and exchange different insights and perspectives to improve IPMG operations.



7
DEC
2023

IPMG conducted a year-end gathering inviting all members and task forces to cherish the past year and strengthen the bond in preparing for the upcoming year.



Members' Contribution to Indonesia



AstraZeneca and the Ministry of Health signed an MoU to implement a national lung cancer screening program with LowDose CT Scan and AI for early detection. They also aim to enhance asthma and COPD care by introducing advanced medication at primary healthcare clinics for better disease management.

In honor of World Lung Cancer Awareness month, AstraZeneca Young Health Program "Lungs of Tomorrow" empowers youth to promote healthy choices and advocate for community health. Partnering with the Ministry of Health, the program encourages early diagnosis by motivating teenagers to encourage their parents to participate in the Lung Cancer Screening program.



AstraZeneca

Coordinating Minister for Maritime and Investment, Luhut Pandjaitan visited our AZ Forest program in Citarum, West Java, and was impressed by the capacity to grow 2.6 million seedlings, leading to over 4 million trees planted and the education of 20,000 farmers in sustainable practices.

AstraZeneca was appointed by the Coordinating Ministry for Maritime and Investment to lead thematic session at the Indonesia Sustainability Forum (ISF). This engagement resulted in the healthcare sector joining the Zero Carbon movement through a historical Healthcare Sustainability Pledge.

In support of AstraZeneca's Zero Carbon ambition, the Indonesian Food and Drug Authority (BPOM) joined the movement by leading mangrove planting initiatives in North Jakarta. AZI through International Pharmaceutical Manufacturing Group (IPMG) was a key supporter, earning appreciation from BPOM and setting an example for the healthcare value chain.





Bayer initiated a stunting prevention program “CETING or Cegah Stunting” that focuses on access to clean water and sanitation including health education for the community nearby Bayer Cimanggis plant in Cisalak, Depok. This program will reach 2,500 beneficiaries.

Coincided with World Contraception Day 2023, Bayer Indonesia launched Bayer for Her campaign to improve women’s knowledge and awareness on reproductive health.

Bayer Indonesia continues the Bayer for Indonesia program (BISA) which launched in 2020. In 2023, Bayer appointed the NGO, Reach-52 to conduct the program in Banten and East Nusa Tenggara, focusing on nutrition and family planning for maternal health. The program reached 22 communities and 7,500 residents.



B | BRAUN

In line with the 2024 digital health ecosystem transformation strategy framework by the Ministry of Health, B. Braun presents a digital microscope, namely Aesculap Aeos to support Indonesian neurosurgeons.



GSK

Glaxo Wellcome Indonesia and PT Prodia Widyahusada Tbk signed a Memorandum of Understanding (MoU). This strategic partnership is expected to expand public access to vaccinations across all age ranges.



In expanding access to vaccination as a disease prevention measure, GSK is partnering with technology-based health service Good Doctor. The cooperation agreement between GSK and Good Doctor was signed by both parties in commemoration of National Health Day by the Ministry of Health at the Jakarta Convention Center on November 10, 2023.



GSK

GSK has partnered with Indonesian Pulmonary Doctors Association (PDPI) to launch the “Peduli Paru OK” initiative. This collaborative agreement marks a significant milestone to spread awareness on respiratory disease like chronic obstructive pulmonary disease (COPD) and Asthma through initiation of Peduli Paru OK public campaign, as well as accelerating the deployment of digital continuous medical education (CME) platform for pulmonologists and General Practitioner called EducAIR. The Peduli Paru OK Campaign aims to inspire and support at-risk individuals, providing them with the latest information on respiratory diseases. It also encourages timely consultation with doctors for proper management. To commemorate World COPD day, GSK Indonesia proudly introduced @peduliparu_ok, a new digital public education platform, during the car free day at Sudirman-Thamrin, Jakarta.

GSK

To mark National Health Day on November 12th, GSK Indonesia proudly launched @AyoKitaVaksin, a new digital education platform accessible on Instagram and TikTok with aims to enhance public awareness and knowledge about prevention and vaccination for people of all ages.



In commemoration of World Immunization Week 2023, GSK Indonesia in partnership with Ministry of Health, Media, and Parents Community conducted Media Briefing with theme "Big Catch Up - Together Protecting Golden Generation", aligned with WHO global theme.



Johnson&Johnson

Johnson & Johnson in Indonesia collaborated with Indonesia's Mental Health Hospitals and Drug Dependence Association (ARSAWAKOI) to hold a symposium about mental health.



MERCK

Merck and BKKBN signed an agreement to lower stunting rate.

Merck Indonesia in collaboration with In Vitro Fertilization (IAIVF) & Indonesian Association of Health Insurance and Managed Care (PAMJAKI) are driving fertility treatment access and coverage in private insurance.

Partnership with private hospital/clinic to increase public awareness of prediabetes and activation of high-risk population. In addition, Merck also conducted partnerships with targeted corporations to increase employee awareness of prediabetes, activation of high-risk population and drive policy change for prediabetes early detection and treatment.



MERCK

LMIC Thyroid RAISE Program, a collaborative initiative to drive early detection, screening, HCP capability advancement and policy shaping in Thyroid Management with aims to increase thyroid diagnosis and treatment rate.

In the first year of RAISE implementation, it has been reaching >3,900 HCPs for the Thyroid screening training; >57,400 patients of digital screening; >15,700 THS tests conducted. Resulting 3% of treatment rate (increase from <1% previously).

Series of sustainability activities with communities.



mundi pharma

Mundipharma Healthcare Indonesia launched the "#JanganBerhenti Sedia Kebaikan Bersama Betadine" campaign to commemorate the World Oral Health Day and to welcome Ramadan season.





PT. Mitsubishi Tanabe Pharma Indonesia

Mitsubishi Tanabe Pharma Indonesia (MTID) together with the Bandung City Vocational School 7 Alumni Association (IKA ALKIM 7) carried out reforestation on Mount Puntang District Bandung by planting 500 tree seedlings. (March 2-3, 2024)



MTID together with the Indonesian Red Cross (PMI) Bandung City carry out humanitarian Blood Donation activities regularly every 3 months. During FY2023 MTID Factory has donated 193 tubes of blood.



MTID participated in the Net-Zero Carbon Program organized by the Indonesian Food and Drug Supervisory Agency (BPOM) on October 31, 2023, at the Angke Kapuk Nature Tourism Park (TWAAK), Pantai Indah Kapuk (PIK), Jakarta.





PT. Mitsubishi Tanabe Pharma Indonesia

MTID together with the Bandung City Government, Cinambo District, on August 3, 2023, planted ornamental plants on Jl. Rumah Sakit.



MTID participated in "Procurement of Health Equipment and Medicines Based on a Priority Scale for Aid to Palestine from Indonesia" coordinated by the Indonesian Ministry of Health with donated 900 ampoules of Xylocaine Injection 2%. (Oct 31, 2023)





MSD signed an agreement to collaborate with Bio Farma for local production of the 4-valent human papillomavirus (HPV) vaccine through technology transfer cooperation.



Merck Sharp & Dohme (MSD) Indonesia continues to support the expansion of HPV immunization coverage nationally, one of which is through the School Based Immunization Month (BIAS) program.



Merck Sharp & Dohme (MSD) Indonesia collaborates with the Indonesian Cancer Foundation (YKI) to hold an art exhibition campaigning and improving people's awareness on cancer.





The Affordability Project, a collaboration between the Ministry of Health, Embassy of Denmark for Indonesia, the West Java Health Agency, PERKENI, PEDI, and NNID, targeted diabetes in rural West Java. They screened over 230,000 people, diagnosed 1,000 cases with high blood sugar levels, and provided free insulin to those patients for a year.

Novo Nordisk Indonesia team renovated a neglected satellite primary care facility, Puskesmas Pembantu (Pustu) Cinerang, in a remote area of West Java. Uniquely, the renovation embraced sustainability by incorporating 674 kilograms of recycled plastic waste as building materials.





Novartis Indonesia and the Ministry of Health collaborated to hold educational campaign titled "Rights to Smile: Women Talk about Breast Cancer" to improve the awareness of Indonesian women to take control over their welfare and health.



The high number of Tuberculosis (TBC) cases in the country has prompted PT Amerta Indah Otsuka to create the "Free TBC at Workplaces" program. This program, which has been implemented since mid-2022, has received full support from the government, especially the Ministry of Health and the Ministry of Manpower.





Pfizer Indonesia has won The Gold Standard Award in the Corporate Communications category for Asia Pacific and the Middle East. This award was given by the regional public relations professional association in Asia Pacific in Singapore for the company category.

In an effort to raise the awareness about diabetes prevention and management, as well as protecting oneself from pneumonia, Pfizer Indonesia partnered with Eka Hospital to hold Health Talk to commemorate Diabetes Day and Pneumonia Day which fall in November.



Roche


Roche Indonesia holds fundraising for children with cancer through the Indonesia Care for Cancer Kids Foundation (YKAKI). Through the Roche Children's Walk movement, the employees of Roche Indonesia managed to raise Rp138 million.



MoU signed with Universitas Gadjah Mada to open oncology nurse specialist program starting in the academic year of 2025.



ECHO Telementoring formally adopted by the Ministry of Health.



Roche

7 nurses enrolled in oncology nurse specialist scholars in Universitas Indonesia with the 7 first batch of oncology nurse specialist graduated from their study in 2023.

Following our collaboration with RS Kanker Dharmais and TMC India, 21 Cancer Patient Navigators from 7 hospitals have practiced their role during their learning process.





Takeda joined hands with the University of Indonesia Center for Social Security Studies (PKJS UI) in organizing a talk show to promote #EmbraceEquity. Highlighted the theme "Women's Leadership in Public Health", the event aimed to raise awareness of women's role in improving public health in Indonesia, especially through innovative healthcare solutions.

Takeda partnered with The Ministry of Women Empowerment and Child Protection (KemenPPPA), the Ministry of Health (Kemenkes), and the University of Indonesia Center for Social Security Studies (PKJS UI), united diverse healthcare stakeholders to address crucial public health issues, including dengue, through a compelling public discussion themed "Creating a Healthy and Safe Environment for Children" during National Children's Day.





Takeda co-initiated the joint coalition for the fight against dengue with the DPR RI Health Caucus, the Ministry of Health, Bio Farma, the World Mosquito Program, and other key stakeholders. This initiative aims to strengthen efforts towards zero dengue deaths by 2030 in Indonesia, supporting the National Strategy on Dengue Management 2021-2025. With Indonesia battling a surge in dengue cases, KOBAR Lawan Dengue aims to increase public awareness and implement sustainable actions, highlighting Takeda's unwavering commitment to combating dengue and protecting the health of the Indonesian population.


The Ministry of Health of Indonesia and Takeda have launched the #Ayo3MplusVaksinDBD campaign, forming strong public-private partnerships. This initiative empowers communities, trains healthcare professionals, supports the zero dengue deaths by 2030 program, and enhances cooperation among policymakers using an integrated approach and data synchronization with SIARVI. Recognized for its impact and innovation, the campaign received the prestigious PR Indonesia Award 2024.





In September, Takeda and the Cancer Information and Support Center (CISC) partnered to host an inspiring lymphoma awareness event in Jakarta, which gathered nearly 60 participants, including national journalists and patients. This impactful initiative demonstrated Takeda and CISC's unwavering commitment to empowering the lymphoma community and fostering hope through engaging sessions on symptoms, early diagnosis, innovative treatments, and emotional well-being.





Members' Awards and Recognitions

W
Actavis

PT Actavis Indonesia

- ✦ PROPER Award. Blue Rank. (Complied with Environmental Regulatory).

AstraZeneca

PT AstraZeneca Indonesia

- ✦ Best Places to Work.
- ✦ Asia's Most Inspiring Executives.
- ✦ Asia's Most Influential Companies.
- ✦ Borneo Award: Corporate Excellence in the Pharmaceutical Sector for Sustainable Solutions at The IBR Borneo Awards 2023.
- ✦ PPKM Award from Ministry of Health.



PT Bayer Indonesia

- ✦ PROPER - Blue rating.
- ✦ The Indonesia Operational Excellence Conference and Award (OPEXCON) 2023: Four bronze awards for innovation category.
- ✦ Award from Depok City government for implementing a smoking-free zone throughout the factory area.

B|BRAUN

B. Braun Indonesia

- ✦ Great Place To Work certification issued by Great Place To Work Institute.

PT Boehringer Ingelheim Indonesia



- ❖ PT Boehringer Ingelheim Indonesia. Platinum Award The Best Green Industry in Pharmaceutical Sector by BPOM.
- ❖ PT Boehringer Ingelheim Indonesia Human Pharma Supply Bogor. Silver Award. Increasing Productivity & Process Acceleration for Solid Technology. By SHIFT Indonesia, Operational Excellence Conference and Award 2023.
- ❖ PT Boehringer Ingelheim Indonesia Human Pharma Supply Bogor Bronze Award by SHIFT Indonesia:
 - 1) Excellence Waste Management.
 - 2) Double Capacity for Suppository Product & Optimization Efficiency for Liquid Products by 100%.
 - 3) Increase QO Productivity.
- ❖ PT Boehringer Ingelheim Indonesia Human Pharma Supply Bogor Naker Award 2023 Paramakarya (Top 10 in Productivity & Quality) by The Ministry of Manpower.
- ❖ PT Boehringer Ingelheim Indonesia Animal Health Division. The Indonesian Government Recognition on World Rabies Day: Rabies Vaccine Donation by The Ministry of Health.

PT Glaxo Wellcome Indonesia (GSK)



- ❖ Gold for Environmental Sustainability Award under Pharmaceutical Industry Category by BPOM.
- ❖ GSK Indonesia winning Top Employer Indonesia.
- ❖ GSK Indonesia Head Office is receive the WELL Health & Safety Rating from International Well Building Institute.



PT Merck Tbk

- ❖ HR Excellence Award from SWA Magazine in the Wellbeing Management; Learning and Development and Knowledge Management, HR Digitation and People Analytic categories.
- ❖ Indonesia Best Business Transformation 2023 Award from SWA Magazine.
- ❖ PPKM Award from the Ministry of Health of the Republic of Indonesia for its contribution to handling COVID-19 in Indonesia.
- ❖ Merck was awarded as The Best Healthcare Sector of Investortrust Companies 2023 by Investortrust.id.
- ❖ 2023 CSA Award, Best Healthcare Sector on the Development Board by the Indonesian Securities Analysts Association (AAEI).
- ❖ Authorized Economic Operation (AEO) certification by the Directorate General of Customs and Excise, Ministry of Finance of the Republic of Indonesia. Certification period: December 17, 2023 - December 17, 2028.



PT Mitsubishi Tanabe Pharma Indonesia

- ❖ 3rd Place Award for Foreign Investment with the Largest Level of Compliance and Value-Added Investment Realization on 2022 of Bandung City on December 5, 2023.
- ❖ PROPER Award Blue Level signed on December 15, 2023.



PT Merck Sharp & Dohme Indonesia

- ❖ HR Excellence Awards Indonesia 2023 - Excellence in Diversity, Equity and Inclusion.



PT Novo Nordisk Indonesia

- ❖ Indonesia Best Place to Work 2023 issued by The Best Places to Work Organization

PT Otsuka Indonesia



- ❖ Environmental Sustainability Titanium Award for Pharmaceutical and Food Industry by BPOM.
- ❖ CSR Award for Health Sector by Malang Regency.

PT Pfizer Indonesia



- ❖ PRCA Asia Pacific's Gold Standard Award for Corporate Communications for HigherHeight program.

PT Roche Indonesia



- ❖ Roche was named as one of biopharma companies recipients of the top COVID-19 National Award (PPKM).

PT Takeda Innovative Medicines



- ❖ PR Indonesia Award 2024 (for activities in 2023).





CHAPTER 3

IPMG'S PRIORITIES

a. Key Priorities and Task Force Activities in 2023.....	80
b. 2024 Priorities	88



Key Priorities and Task Force Activities in 2023

The eye-opening fact from an acclaimed study on Global Access to Innovative Medicines presented at the 2022 G20 showed that only nine percent of innovative medicines are available in Indonesia, with an average of 40 months delay since the first global launch. Yet, another 24 months wait before an innovative medicine is accessible to BPJS Kesehatan patients. This finding raised an urgency for immediate public health intervention.

The aftermath of the low access to new medicines could ploddingly impact the degree of healthiness in Indonesia over time. A collective collaboration approach is needed to eliminate these challenges through triple helix interaction between government, industry, and academia. The

Ministry of Health has shown political will to increase the availability and access of new medicines embedded within the six pillars of healthcare transformation and other recently released regulations. IPMG, as one of the trusted government partners, is committed to working hand-in-hand with the government and academia to address the challenges for a better quality of life and health outcomes for Indonesians.

In 2023, IPMG engaged with various stakeholders in different advocacy fields through task forces to increase the availability and accessibility of new medicines. The commitment and spirit to bring innovation for Indonesia patients are reflected through four advocacy priorities, namely:

- access to innovative medicines,
- clarity and transparency in the government procurement,
- address localization barriers, and
- boost the value of innovation.

These advocacy priorities are manifested further in activities and initiatives by each task force.





Industrial Policy Task Force

Role and Responsibility

In supporting the Indonesian government's agenda to expedite the industrialization and transformation of its healthcare system industry, the IPMG Industrial Policy Task Force is present to observe and advocate for government policies conducive to a healthy business environment. This applies to both national and multinational entities. With highly experienced members and sponsors in the industry, the task force is up to date with many results that leave an impact.

Our role is to encourage government policies that support a conducive business environment for multinational entities, fostering innovation and increasing the healthy growth of the pharmaceutical industry as a whole. The statutes and regulations addressed include the TKDN, halal certification, IP (Patent Law), Health Minister Decree 1010, and others.

Achievement

In 2023, The Industrial Policy Task Force was actively involved in discussions and initiatives regarding healthcare-related policy and regulations with critical stakeholders, including the Ministry of Health, Ministry of Industry, BPOM, Chamber of Commerce, and think tanks.

The Omnibus Health Law and its derivatives had been the center for the Industrial Policy Task Force. During the dynamic process of developing regulations, the task force initiates stakeholders' dialog and provides some constructive input as part of IPMG standpoints towards the draft of government regulations on health during the public hearing session. Besides the Omnibus Health Law and its derivatives, the Industrial Policy task force was also involved in narrative development and advocating for Local Content Requirement (LCR/TKDN), halal certification, and import barriers on pharmaceutical salt.

SPONSOR:

M. Idham Hamzah
(PT Transfarma Medika Indah)

LEAD:

Bambang Chriswanto
(PT Pfizer Indonesia)

CO-LEAD:

Rizman Abudaeri
(PT AstraZeneca Indonesia)

MEMBERS:

1. **Marendra Sadikin**
(PT Merck Sharp & Dohme Indonesia)
2. **Wanda Harahap**
(PT Abbott Indonesia)
3. **Khoirul Amin**
(PT Pfizer Indonesia)
4. **Rosalina Saleh**
(PT Novartis Indonesia)
5. **Reswita D. Gisriani**
(PT Glaxo Wellcome Indonesia)
6. **Hoerry Satriyo**
(PT AstraZeneca Indonesia)
7. **Widodo Tri Wibowo**
(PT Novartis Indonesia)
8. **Andy Lee**
(PT Johnson & Johnson Indonesia Two)
9. **Dudit Triyanto**
(PT Merck Sharp & Dohme Indonesia)



Regulatory Affairs Task Force

SPONSOR:

Selly Kartika
(PT Abbott Indonesia)

LEAD:

Firnando Sianturi
(PT Johnson & Johnson Indonesia Two)

CO-LEAD:

Destita Khairilisani
(PT Abbott Indonesia)

MEMBERS:

1. **Anna Emmy Kurniaty**
(PT AstraZeneca Indonesia)
2. **Henny Purwantini**
(PT Boehringer Ingelheim Indonesia)
3. **Iin Nurhayati**
(PT Pfizer Indonesia)
4. **Desti Wibowo**
(PT Merck Tbk)
5. **Furqoni C. Mahastika**
(PT Transfarma Medika Indah)

Role and Responsibility


In supporting the Indonesian government's agenda to expedite With a long history and experience in healthcare and pharmaceutical research and development, the IPMG Regulatory Affairs Task Force aims to build a performing regulatory framework that is a seamless and reliable regulatory framework that combines efficient processes, safety, quality, and speed (timely approval process). The Task Force envisioned an efficient regulatory system that protects public health and is conducive to the pharmaceutical industry.

In addition, to ensure swift drug approvals and international best practices, the task force actively provides recommendations upon requests, anticipates and investigates bottlenecks, explores safety measures, and analyses regulations.

The Task Force aimed to simplify package insert management through e-labeling, clarify orphan drugs' definition and procedures, amend the Brown Book regarding the flexibility to register multiple sites/sources to increase resilience and avoid supply shortages, align halal labeling with BPJPH regulation, and utilize Real-World Evidence data to inform regulatory decision-making and support registration.

In 2023, the Regulatory Task Force has been engaged with key stakeholders such as BPOM and the Ministry of Health and accomplished the following contributions:

- The IPMG e-labeling pilot project was launched on September 1st, 2023
- IPMG submitted and discussed the proposed draft of the Orphan Drug guidelines with BPOM
- Submitted recommendations on Orphan Drugs/Rare Disease Guidelines to the Directorate of Pharmaceutical and Medical Devices Resilience
- IPMG conducted a Focus Group Discussion regarding Medicine Quality Standards in Indonesia and Indonesian Pharmacopeia Supplements
- IPMG submitted input during the public hearing period regarding the draft of government regulations on health (Law number 17 concerning Health and its Government Regulation).



JKN Drug Enlistment Task Force

Role and Responsibility

The IPMG JKN Drug Enlistment Task Force's leading role and responsibility is to improve transparency, enable better decision-making, and streamline the drug enlistment system in BPJS. The Task Force hopes to simplify the procurement process to improve the accessibility of innovative medicines.

Preventing any poorly executed value assessment or HTA program that would reduce access to medical technology and removing disincentives to the introduction of healthcare innovation are strategic keystones for the foundation of a robust healthcare system. This task force applies best practices to ensure drug enlistment for FORNAS (and HTA or other value assessment programs) to better contribute to improved patient and public health. This supports evidence-based decision-making by policymakers, payers, and healthcare providers.

Achievement

In 2023, the JKN Drugs Enlistment Task Force worked closely with the Procurement of Goods and Services Bureau from the Ministry of Health to ensure a smooth and streamlined government procurement process.

The Task Force obtained:

- Flawless access to all systems on e-catalog and BPJS claim system. This was achieved by having the relevant systems ready on time upon the new cycle of e-catalog.
- Innovative medicines with unique profiles would no longer be negotiated at the hospital level to prevent misconduct.
- Clarity on the involvement of BPJS and MoH in the price reference claiming system
- Clarity on the new JKN tariff
- Clarity on the new FORNAS process regarding price negotiation
- Clarity on the category of chronic disease medicines (non-referral program/PRB)

SPONSOR:

Nora Siagian
(PT Pfizer Indonesia)

LEAD:

Banarsono Trimandojo
(PT Novo Nordisk Indonesia)

CO-LEAD:

Andy Prabowo
(PT Boehringer Ingelheim Indonesia)

MEMBERS:

1. **Bram Baan**
(PT Glaxo Wellcome Indonesia)
2. **Eko Wahyudi**
(PT Merck Tbk)
3. **Dudit Triyanto**
(PT Merck Sharp & Dohme Indonesia)
4. **Welly**
(PT Takeda Innovative Medicines)
5. **Dias Bachtiar**
(PT Johnson & Johnson Indonesia Two)



Affordability Task Force

SPONSOR:

Evie Yulin
(PT Merck Tbk)

LEAD:

Andri Kusandri
(PT Merck Tbk)

CO-LEAD:

Danika Kartasasmita
(PT Pfizer Indonesia)

MEMBERS:

1. **Henny Mansjur**
(PT B. Braun Indonesia)
2. **Aulia Citta Arieni**
(PT Anugerah Pharmindo Lestari)
3. **Marry Purnama**
(PT Novartis Indonesia)

Role and Responsibility

IPMG's Affordability Task Force ensures patients access innovative funding and promotes fair pricing. The Task Force also plans, promotes, and studies multiple Indonesian government programs concerning innovative medicines. To safeguard BPJS from being deficit and to remove physicians' restrictions in prescribing patients with innovative medicines when needed by patients, the Task Force stimulates discussion with key stakeholders to explore various innovative funding solutions, including Coordination of Benefits (CoB).

The task force ensures improvement for patients' sustainable access to innovative medicines and diagnostic procedures. The Task Force optimizes current resources through presenting various innovative funding solutions, identification of potential streams, and provides multidimensional financing for public health through mobilization of the public-private partnership scheme. Affordability is achieved through the improved efficiency and effectiveness of public expenditure within various sectors and the correction of systemic constraints.

Achievement

- Throughout 2023, the Affordability Task Force participated in a series of discussions and Forum Group Discussions (FGD) held by and with the Ministry of Health (Pusjak PDK, Directorate of Pharmaceutical and Medical Device Resilience), BPJS, and academia. The Task Force also provided MoH with innovative funding case studies from various countries for further analysis.
- In addition, the Task Force also provided verbal and written input to Health Law Number 17 to ensure fair pricing and patients' access to innovative medicine.
- The task force has set its priority advocacy to enhance the health coverage of national health insurance through Coordination of Benefits (CoB) or top-up insurance scheme implementation (KAPJ).
- Furthermore, the Affordability Task Force also ensures the access of innovative medicines to the national formulary through Health Technology Analysis (HTA).



Communications Task Force

Role and Responsibility

To build more meaningful conversations and establish positive endorsements from key stakeholders, the IPMG Communications Task Force exists to amplify IPMG advocacy through the media and promote IPMG's key initiatives utilizing multiple communication channels. The IPMG Communications Task Force has conducted various initiatives to better position the organization as the key strategic partner in the healthcare sector.

Not only did the IPMG Communication Task Force reached out to external stakeholders, but it also shared IPMG's values and contributions to internal stakeholders to maintain close engagement among members. Effective dialogue and stakeholder engagement were done consistently to maintain good rapport with stakeholders and improve IPMG positioning, which promotes positive impact. By assembling materials built on solid data, developing key messages, and creating a public image – while also strongly developing an understanding of medicine and the pharmaceutical industry – the Task Force presented the urgency of improving innovative medicines availability and accessibility. This task force developed, planned, and delivered key messages for wide consumption.

Achievement

In 2023, the Communications Task Force has accomplished several contributions, namely:

- Produced IPMG Annual Report 2022
- Conducted a Media Editors Gathering to discuss about Indonesia's access and availability of innovative medicines
- Distributed press releases to amplify IPMG's advocacy to improve patients access and present the significance of doing business with strong code of conduct
- Collaborated with the Ministry of Health for the 59th National Health Day and continued discussion about improving patients' access to innovative medicines through innovative funding
- 1 exclusive media interview
- 4 press releases distribution
- 132 coverages of news articles

SPONSOR:

George Stylianou
(PT Merck Sharp & Dohme Indonesia)

LEAD:

Reswita D. Gisriani
(PT Glaxo Wellcome Indonesia)

CO-LEAD:

Sri Libri
(PT Bayer Indonesia)

MEMBERS:

1. **Hanum Yahya**
(PT Novartis Indonesia)
2. **Wanda Harahap**
(PT Abbott Indonesia)
3. **Nabila Astari**
(PT Merck Sharp & Dohme Indonesia)
4. **Ferdo Pratama**
(PT Takeda Innovative Medicines Indonesia)
5. **Millatul Hanifiyyah**
(PT Glaxo Wellcome Indonesia)



Ethics, Medical and Patient Safety Task Force

SPONSOR:

Khalid Ibrahim
(PT Novartis Indonesia)

LEAD:

Miranda Andamsari
(PT Merck Tbk)

CO-LEAD:

dr. Dian Rospita
(PT Johnson & Johnson Indonesia Two)

MEMBERS:

1. **Sucipto Kuntoro**
(PT Astellas Pharma Indonesia)
2. **Ute Nurdin Ramdani**
(PT Mitsubishi Tanabe Pharma Indonesia)
3. **Wiratsari Pinastika**
(PT Boehringer Ingelheim Indonesia)
4. **Emidawati**
(PT Novartis Indonesia)
5. **Aprilia De Leon**
(PT Roche Indonesia)
6. **dr. Richard Santoso**
(PT Pfizer Indonesia)
7. **dr. Mayuresh**
(PT Novartis Indonesia)
8. **dr. Ratna Widyasari**
(PT Merck Tbk)
9. **Fachria Evi Yanthi**
(PT Pfizer Indonesia)
10. **Febria Rehinatha**
(PT AstraZeneca Indonesia)

Role and Responsibility

Patient safety, high-quality standards, and ethical treatment are the core DNA of the healthcare ecosystem. The Ethics, Medical, and Patient Safety Task Force of IPMG exists to firmly uphold the highest professional standards and monitor healthcare industry activity to deliver proper advocacy for patients.


The Ethics, Medical, and Patient Safety Task Force's role is to oversee industry activities and uphold the highest professional standards for the promotion of medicine, as well as to improve the local clinical research landscape and contribute to the implementation of international standards of clinical trials. The task force must ensure that IPMG's Code of Ethics (CoE) always aligns with global compliance standards and local laws and regulations. Through education and information sharing, knowledgeable leadership with high standards fosters a culture of compliance. The task force maintains a level playing field and encourages responsible self-regulation. We are instrumental in forming alliances with healthcare stakeholders to advocate the IPMG CoE to a broader audience.

Achievement

In 2023, the Ethics, Medical, and Patient Safety Task Force was closely engaged with the Corruption Eradication Commission to uphold the highest ethical business standard. Furthermore, in fulfilling its role, the task force has accomplished some contributions, as follows:

- Ensuring IPMG's Code of Ethics CoE aligns with any updated IFPMA guidelines and local regulations.
- Participating in discussions with the Indonesia Corruption Eradication Commission, Ministry of Health, and Gakeslab regarding challenges faced by the healthcare industry in Indonesia.
- Participating in the National Anti-corruption Day 2023 in collaboration with the Corruption Eradication Commission and opening IPMG's Booth.
- Safeguarding ethical business practices among IPMG members and handling official complaints procedures raised to the EMPS Task Force.

- Collaborating with external partners such as The Indonesian Association for The Study of Medicinals (IASMED) to elevate public awareness of the opportunities and challenges of global clinical trial participation ('Diskusi Terbuka Uji Klinik')
- Contributing to the IPMG's input for the health bill draft, primarily related to clinical research topics.
- Several discussions amongst IPMG Ethic Practice Members regarding relevant topics, i.e., Medical Association Fees, Speaker Engagements, etc.



Partnering for Health Advancement Task Force

Role and Responsibility

The IPMG Partnering for Health Advancement Task Force aims to contribute to the national agenda of building health system sustainability and resilience and achieving UHC. To deliver on these priorities, the Task Force strives, through collaboration and partnership, to improve the healthcare workforce's capabilities, encourage productivity and innovation, and co-shape the regulatory landscape for a more conducive ecosystem for health (medical) technology advancement.

Achievement

In 2023, the Partnering for Health Advancement Task Force worked with the Directorate of Pharmaceutical and Medical Devices Resiliency on a roadmap (The BIMA project) to address the urgency of increasing access and availability of innovative medicines in Indonesia. The Task Force also engaged with the Ministry of Health in policy dialogues to improve the adoption of the World Health Organization Essential Medicines List (WHO EML) in the National Formulary.

SPONSOR:


Ait-Allah Mejri
(PT Roche Indonesia)

LEAD:

Lucia Erniawati
(PT Roche Indonesia)

MEMBERS:

1. **Hendra Wijaya**
(PT Pfizer Indonesia)
2. **Khoirul Amin**
(PT Pfizer Indonesia)
3. **Wanda Harahap**
(PT Abbott Indonesia)
4. **Reswita D. Gisriani**
(PT Glaxo Wellcome Indonesia)



2024 Priorities

Faster and Greater Access to Innovative Medicines



1. To explore and drive JKN innovative funding solutions, and identify potential routes to optimize current resources through COB/KAPJ
2. To improve Health Technology Assessment (HTA) process, governance, and capabilities.
3. To remove the practice of a 2-year wait+ prior to Fornas listing.
4. To promote Pharmacopeia interchangeability.



Address Coercive Localization Barriers

1. To shape government policies that increase market attractiveness and minimize barriers to access to innovative medicine, resulting in the long-term sustainable growth of the pharmaceutical industry.
2. To co-create a pro-growth and pro-innovation environment that facilitates access to innovative medicines.





Clarity and Transparency in Government Procurement

To increase transparency and decision-making and streamline the process of the drug enlistment system in BPJS.



Enhance Perception and Value of IPMG Contributions

1. To emphasize IPMG's presence as a local partner and cement its R&D expertise to support the national pharmaceutical resiliency agenda.
2. To demonstrate the system and societal value of our presence and innovations.

IPMG Secretariat



Ani Rahardjo
Executive Director



**Atika Gadis
Parengkuan**
Public Affairs and
Communications
Lead



**Nathanael
Jusaac Lie**
Project Officer



**Jony
D. Radja**
Administration
and Membership
Services Manager

International Pharmaceutical Manufacturers Group (IPMG)

Pondok Indah Office Tower 1. Third Floor. Suite 308
Jalan Sultan Iskandar Muda Kavling V-TA
Jakarta 12310
Indonesia

Phone : +62 21 7697531
Fax : +62 21 7697532
Email : ipmg@ipmg-online.com
Website : www.ipmg-online.com
LinkedIn : IPMG Int'l Pharma Manufacturers Group



